Related Experiment Video
Updated: Mar 26, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Common and rare CARD14 gene variants affect the antitumour necrosis factor response among patients with psoriasis
P Coto-Segura1,2, D González-Fernández1, A Batalla1
1Department of Dermatology, Hospital Universitario Central Asturias, Oviedo, Spain.
Insights
Specific CARD14 gene variants may influence patient response to anti-tumour necrosis factor (anti-TNF) therapies for psoriasis. The common p.Arg820Trp variant and rare missense variants were linked to better treatment outcomes.
Area of Science:
- Genetics and immunology
- Dermatology
- Pharmacogenomics
Background:
- The CARD14 gene is implicated in inflammatory pathways and psoriasis development.
- CARD14 variants are associated with psoriasis risk.
- This study investigates CARD14 variants' role in anti-TNF therapy response.
Purpose of the Study:
- To determine if CARD14 gene variants correlate with positive responses to anti-tumour necrosis factor (anti-TNF) therapies in psoriasis patients.
Main Methods:
- Next-generation sequencing of the CARD14 gene in 116 psoriasis patients.
- Analysis of allele and genotype frequencies in responders versus non-responders.
Main Results:
- A common CARD14 variant, rs11652075 CC (p.Arg820Trp), was significantly more frequent in responders (P = 0.01).
- Rare CARD14 variants (p.Glu422Lys and p.Arg682Trp) were also observed more frequently in responders.
Conclusions:
- The CARD14 p.Arg820Trp variant may significantly impact anti-TNF therapy effectiveness in psoriasis.
- Rare CARD14 missense variants might also predict a better response to these therapies.
Background:
The CARD14 gene encodes a protein that enhances nuclear factor (NF)-κB activation and the upregulation of proinflammatory pathway genes. CARD14 is upregulated in psoriatic vs. normal skin, and rare and common CARD14 variants have been associated with the risk of developing psoriasis. Our hypothesis was that CARD14 variants could also influence the response to antitumour necrosis factor (anti-TNF) therapies among patients with psoriasis.
Objectives:
To determine whether CARD14 gene variants were linked to a significant positive anti-TNF response in patients with psoriasis.
Methods:
DNA from 116 patients with psoriasis was subjected to next-generation sequencing of the CARD14 gene. All of the patients were nonresponders or had contraindications to conventional systemic treatments.
Results:
A reduction of at least 75% in Psoriasis Area and Severity Index (PASI 75) at week 24 was considered a positive response to treatment. In total 116 patients (79 responders and 37 nonresponders) were next-generation sequenced, and we identified five nucleotide variants that would result in missense amino acid changes. These variants were determined in all of the patients, and allele and genotype frequencies were compared between the two groups. We found a significantly higher frequency of rs11652075 CC (p.Arg820Trp) among the group with a positive response (P = 0.01, odds ratio 3.71, 95% confidence interval 1.30-10.51). Furthermore, among responders, six patients were heterozygous carriers of the rare p.Glu422Lys variant, and two patients were heterozygous for p.Arg682Trp (P = 0.04).
Conclusions:
The common CARD14 p.Arg820Trp variant might have a significant effect on the response to anti-TNF therapies among patients with psoriasis. In addition, rare CARD14 missense variants could also predispose to a better response.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pharmacogenomics: Identification of New Drug Targets
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

